Therapeutic Approach

Archive: June, 2011

Ritter Pharmaceuticals, Inc. Announces First Patient Enrollment in its Phase 2 Clinical Study of RP-G28 for the Treatment of Lactose Intolerance

LOS ANGELES, CA – June 21, 2011 – Ritter Pharmaceuticals, Inc. (Ritter), a pharmaceutical company with a focus on digestive diseases, announced today that clinical investigators have enrolled the first patient in its randomized, double-blind, placebo-controlled Phase 2 study of RP-G28 in patients with symptoms associated with lactose intolerance. The study, which is being conducted […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD